Stay updated with breaking news from Arcus Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of...
HAYWARD, Calif.--(BUSINESS WIRE)--Jan 16, 2024--
Median Overall Survival was 15.7 months for all patients treated with 100 mg quemliclustat-based regimens in the ARC-8 study, which exceeds the historical benchmark data for chemotherapy alone A...
Merck said on Thursday a combination treatment testing a new type of immunotherapy failed to significantly slow disease progression in lung cancer patients who did not respond to previous treatments.
– Phase 1b/2 clinical trial expected to begin enrolling patients before year-end 2023 – ...